In a report released today, Gbola Amusa from Chardan Capital maintained a Hold rating on Esperion (NASDAQ: ESPR), with a price target of $32.50. The company’s shares closed yesterday at $41.55.
Amusa noted:
“We also note Esperion management expressed there was no need to discuss these deaths further as part of the event as individual patient narratives were disclosed on 8 May (and Esperion’s President and CEO published a blog post on 5 June).”
According to TipRanks.com, Amusa is a top 100 analyst with an average return of 29.6% and a 55.5% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.
Currently, the analyst consensus on Esperion is a Moderate Buy with an average price target of $80.14.
See today’s analyst top recommended stocks >>
Based on Esperion’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $46.13 million. In comparison, last year the company had a GAAP net loss of $43.34 million.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ESPR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
